Regulation and immunotherapy responses of NK cells (and T cells) against tumors
In person only
Most immunotherapy efforts aim to mobilize CD8+ T cells against cancer cells. Many tumors lack many neoantigens, and others are selected for partial or complete loss of MHC I, even before immunotherapy intervention. Checkpoint immunotherapy further exacerbates this problem as it preferentially amplifies CD8 cytotoxic effector cell activity, which targets MHC I presented tumor epitopes, imposing strong selection for loss of MHC I or other antigen presentation functions. Our work focuses on mobilizing NK cells and CD4 T cells to attack tumors. Innate immune system agonists and engineered cytokines synergize in eliciting such responses. I will discuss the impact and mechanisms underlying this approach, as examined in mouse cancer models, and its potential for preventing acquired resistance to checkpoint immunotherapy.
Date:
29 April 2024, 12:00 (Monday, 2nd week, Trinity 2024)
Venue:
Kennedy Institute of Rheumatology, Headington OX3 7FY
Venue Details:
Bernard Sunley Lecture Theatre
Speaker:
Professor David Raulet (UC Berkeley)
Organising department:
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS)
Organiser:
Doris Chan (Kennedy Institute of Rheumatology)
Organiser contact email address:
doris.chan@kennedy.ox.ac.uk
Host:
Prof Mark Coles (Kennedy Institute of Rheumatology )
Part of:
Kennedy Institute Seminars
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Doris Chan
